Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment

Fichier pdf chargé le 05/02/2019 à 17:13:06

(version éditeur)
TitreDrug combination using an injectable nanomedicine hydrogel for glioblastoma treatment
Type de publicationArticle de revue
AuteurBastiancich, Chiara , Bozzato, Elia , Luyten, Urszula , Danhier, Fabienne , Bastiat, Guillaume , Préat, Véronique
TypeArticle scientifique dans une revue à comité de lecture
Date25 Mars 2019
Titre de la revueInternational Journal of Pharmaceutics
Mots-clésGemcitabine, Glioblastoma, Hydrogel, Local delivery, nanomedicine, Paclitaxel
Résumé en anglais

Lauroyl-gemcitabine lipid nanocapsules (GemC12-LNC) hydrogel, administered intratumorally or perisurgically in the tumor resection cavity, increases animal survival in several orthotopic GBM models. We hypothesized that GemC12-LNC can be used as nanodelivery platform for other drugs, to obtain a combined local therapeutic approach for GBM. Paclitaxel (PTX) was selected as a model molecule and PTX-GemC12-LNC formulation was evaluated in terms of physicochemical and mechanical properties. The PTX-GemC12-LNC hydrogel stability and drug release were evaluated over time showing no significant differences compared to GemC12-LNC. The drug combination was evaluated on several GBM cell lines showing increased cytotoxic activity compared to the original formulation and synergy between PTX and GemC12. Our results suggest that GemC12-LNC hydrogel can be used as nanodelivery platform for dual drug delivery to encapsulate active agents with different mechanisms of action to achieve a better antitumor efficacy against GBM or other solid tumors.

URL de la noticehttp://okina.univ-angers.fr/publications/ua18790
Lien vers le document


Titre abrégéInternational Journal of Pharmaceutics